Market Closed -
Nasdaq
04:30:01 2024-04-26 pm EDT
|
5-day change
|
1st Jan Change
|
1.03
USD
|
+1.98%
|
|
+0.98%
|
-33.55%
|
Fiscal Period: December |
2018
|
2019
|
2020
|
2021
|
2022
|
---|
Capitalization
1 |
3,442
|
3,826
|
3,735
|
1,842
|
1,735
|
Enterprise Value (EV)
1 |
2,336
|
3,453
|
2,575
|
1,536
|
1,350
|
P/E ratio
|
-5.52
x
|
-7.67
x
|
-8.18
x
|
-2.75
x
|
-4.16
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
1.93
x
|
0.97
x
|
0.46
x
|
0.15
x
|
0.13
x
|
EV / Revenue
|
1.31
x
|
0.87
x
|
0.31
x
|
0.12
x
|
0.1
x
|
EV / EBITDA
|
-5.99
x
|
-7.17
x
|
-5.61
x
|
-2.5
x
|
-4.09
x
|
EV / FCF
|
-10.6
x
|
-7.48
x
|
124
x
|
-3.24
x
|
12.7
x
|
FCF Yield
|
-9.43%
|
-13.4%
|
0.81%
|
-30.9%
|
7.85%
|
Price to Book
|
2.81
x
|
4.95
x
|
10.5
x
|
-10.7
x
|
-4.2
x
|
Nbr of stocks (in thousands)
|
81,544
|
81,659
|
82,359
|
82,873
|
83,272
|
Reference price
2 |
42.21
|
46.85
|
45.35
|
22.23
|
20.83
|
Announcement Date
|
4/10/19
|
4/16/20
|
4/30/21
|
4/29/22
|
4/28/23
|
Fiscal Period: December |
2017
|
2018
|
2019
|
2020
|
2021
|
2022
|
---|
Net sales
1 |
959.5
|
1,786
|
3,952
|
8,203
|
12,426
|
13,517
|
EBITDA
1 |
-239.8
|
-389.7
|
-481.8
|
-459.3
|
-614.9
|
-330.2
|
EBIT
1 |
-254
|
-400.4
|
-493.5
|
-473.3
|
-642.1
|
-371
|
Operating Margin
|
-26.47%
|
-22.42%
|
-12.49%
|
-5.77%
|
-5.17%
|
-2.74%
|
Earnings before Tax (EBT)
1 |
-249.3
|
-382
|
-501.8
|
-467.1
|
-621
|
-376.1
|
Net income
1 |
-248.6
|
-380.1
|
-499.6
|
-456.5
|
-669.8
|
-416.9
|
Net margin
|
-25.91%
|
-21.28%
|
-12.64%
|
-5.57%
|
-5.39%
|
-3.08%
|
EPS
2 |
-6.905
|
-7.644
|
-6.105
|
-5.541
|
-8.076
|
-5.004
|
Free Cash Flow
1 |
-120.7
|
-220.3
|
-461.8
|
20.76
|
-474.6
|
106
|
FCF margin
|
-12.58%
|
-12.34%
|
-11.69%
|
0.25%
|
-3.82%
|
0.78%
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
5/17/18
|
4/10/19
|
4/16/20
|
4/30/21
|
4/29/22
|
4/28/23
|
Fiscal Period: December |
2017
|
2018
|
2019
|
2020
|
2021
|
2022
|
---|
Net Debt
1 |
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
1 |
461
|
1,107
|
373
|
1,160
|
306
|
385
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
1 |
-121
|
-220
|
-462
|
20.8
|
-475
|
106
|
ROE (net income / shareholders' equity)
|
-37.4%
|
-42.8%
|
-50.2%
|
-44.4%
|
-57%
|
-50.2%
|
ROA (Net income/ Total Assets)
|
-18.6%
|
-21.7%
|
-19.5%
|
-12.8%
|
-13%
|
-7.01%
|
Assets
1 |
1,335
|
1,754
|
2,557
|
3,578
|
5,151
|
5,951
|
Book Value Per Share
2 |
-26.30
|
15.00
|
9.460
|
4.320
|
-2.090
|
-4.960
|
Cash Flow per Share
2 |
4.660
|
10.50
|
7.080
|
14.40
|
7.960
|
8.070
|
Capex
1 |
6.8
|
14.4
|
20
|
25.5
|
62.6
|
31.6
|
Capex / Sales
|
0.71%
|
0.81%
|
0.51%
|
0.31%
|
0.5%
|
0.23%
|
Announcement Date
|
5/17/18
|
4/10/19
|
4/16/20
|
4/30/21
|
4/29/22
|
4/28/23
|
|
1st Jan change
|
Capi.
|
---|
| -33.55% | 86.51M | | +17.35% | 71.39B | | +5.38% | 8.59B | | +6.69% | 8.19B | | -20.96% | 7.91B | | +0.49% | 4.54B | | +17.12% | 4.31B | | -3.38% | 3.93B | | -2.61% | 3.86B | | +22.08% | 3.64B |
Pharmaceuticals Wholesale
|